How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

909 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions

Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01146041 Recruitment Status : Completed First Posted : June 17, 2010 Last Update Posted : June 17, 2010 Sponsor: Dr. Reddy's Laboratories Limited

2010 Clinical Trials

162. Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients (X-MEN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01312363 Recruitment Status : Completed First Posted : March 10, 2011 Last Update Posted : May 4, 2016 Sponsor

2010 Clinical Trials

163. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. (PubMed)

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Assess long-term cost-effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models based on clinical trial efficacy data.Incremental costs and Quality Adjusted Life Years (QALYs) associated with rivastigmine patch and capsule treatment versus best supportive care (BSC) were calculated using two (...) economic models, one based solely on Mini-Mental State Examination (MMSE) scores, and one also incorporating activities of daily living (ADL) scores. The clinical pathway was populated with data from a clinical trial of rivastigmine patch (9.5 mg/24 h) and capsules (12 mg/day) versus placebo. Costs were based on the UK health and social care costs and basic UK National Health Service (NHS) prices. Disease progression was modelled beyond the trial period over 5 years using published equations to predict

2010 International Journal of Geriatric Psychiatry

164. Dementia: assessment, management and support for people living with dementia and their carers

dementia subtypes Managing medicines for all dementia subtypes 1.5.1 For guidance on managing medicines (including covert administration), see the NICE guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. Pharmacological management of Alzheimer's disease Pharmacological management of Alzheimer's disease 1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended (...) as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or or Dementia: assessment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

166. Pharmacological interventions for the treatment of delirium in critically ill adults. (PubMed)

; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and cholinesterase (CHE) inhibitors (n = 1; rivastigmine). Only one of these trials consistently used non-pharmacological interventions that are known to improve patient outcomes in both intervention and control groups.Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome. Results of the NMA showed that the intervention with the smallest ratio of means (RoM (...) antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high-quality evidence).The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate-quality evidence), and the CHE inhibitor rivastigmine was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate-quality evidence). Adverse events often were not reported in these trials or, when reported

2019 Cochrane

167. Parkinson?s disease in adults

for further information. [4] At the time of publication (July 2017), quetiapine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [5] At the time of publication (July 2017), rivastigmine capsules are the only treatment (...) with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [6] At the time of publication (July 2017), cholinesterase inhibitors

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

168. Clinical practice guidelines for pain, agitation, delirium, sedation and mobilisation in the intensive care unit: A Rapid Review

. There is no published evidence that treatment with haloperidol reduces the duration of delirium in adult ICU patients. No evidence ii. Atypical antipsychotics may reduce the duration of delirium in adult ICU patients. Low iii. We do not recommend administering rivastigmine to reduce the duration of delirium in ICU patients. Moderate iv. We do not suggest using antipsychotics in patients at significant risk for torsades de pointes (i.e., patients with baseline prolongation of QTc interval, patients receiving

2019 Monash Health Evidence Reviews

170. Cholinesterase inhibitors for the treatment of delirium in non-ICU settings. (PubMed)

. The risk of bias was low in all domains.The study compared rivastigmine with placebo. We did not find any clear differences between the two groups in terms of duration of delirium (MD -3.6, 95% CI -15.6 to 8.4), adverse events (nausea, RR 0.30, 95% CI 0.01 to 6.29), use of rescue medications (RR 0.13, 95% CI 0.01 to 2.1), mortality (RR 0.10, 95% CI 0.01 to 1.56), and leaving the study early (RR 0.88, 95% CI 0.07 to 11.54). Evidence was not available regarding the severity of delirium, persistent

2018 Cochrane

171. Cholinergic medication for antipsychotic-induced tardive dyskinesia. (PubMed)

, rivastigmine, eptastigmine, metrifonate, xanomeline, cevimeline) for treating antipsychotic-induced TD in people with schizophrenia or other chronic mental illness.An electronic search of the Cochrane Schizophrenia Group's Study-Based Register of Trials (16 July 2015 and April 2017) was undertaken. This register is assembled by extensive searches for randomised controlled trials in many electronic databases, registers of trials, conference proceedings and dissertations. References of all identified studies

2018 Cochrane

172. Peri-operative care of people with dementia

and being in hospital. Key areas of supportconcern: 1 Knowingaboutthepersonwithdementia,forexample, making use of a ‘This is me’ or similar document (see ‘SourcesofFurtherInformation’); Table 2 Importantdruginteractionsbetweendementiamedicationanddrugsusedinanaesthesia. Half-life;hr Recommendation/effect Cholinesteraseinhibitors Galantamine 7 Discontinue a daybeforesurgery Rivastigmine 9 Discontinue a daybeforesurgery Donepezil 70 Notrecommended Memantine 60–100 Carewithketamine

2019 Association of Anaesthetists of GB and Ireland

173. Memantine

Guideline for Deprescribing Cholinesterase Inhibitors and Memantine . Sydney: The University of Sydney; 2018. The full guideline 2018 4. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 (...) Last updated: 11 May 2016 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new

2018 Trip Latest and Greatest

174. Donepezil

analysis). Secondary efficacy measures evaluated cognition, behavior, and function. The dual primary 2009 4. Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer' Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines | NICE Donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 11 May (...) 2016 Share Save Guidance on donepezil ( Aricept ), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (CG42) and replaces NICE technology appraisal guidance on donepezil , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects

2018 Trip Latest and Greatest

175. Drugs for Alzheimer's disease: finally delisted in France!

of copies of which have been downloaded from our website english.prescrire.org (1). In May 2018, France's Minister for Health took this negative harm-benefit balance into account. She decided that, from 1 August 2018, these drugs – donepezil, galantamine, rivastigmine and memantine – would be delisted, i.e. no longer reimbursed by the national health insurance system (2,3). This measure was not unexpected. In late 2016, the French Pharmacoeconomic (Transparency) Committee had concluded that these drugs

2018 Prescrire

176. Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder

in the treatment of posttraumatic stress disorder: a randomized, double-blind study. J Res Med Sci. 2004;9(5):240-4. 45. Ardani AR, Hosseini G, Bordbar MRF, et al. Effect of rivastigmine augmentation in treatment of male patients with combat- related chronic posttraumatic stress disorder: a randomized controlled trial. J Clin Psychopharmacol. 2017 Feb;37(1):54-60. doi: 10.1097/jcp.0000000000000624. PMID: 27930500. 46. Baker DG, Diamond BI, Gillette GM, et al. A double-blind, randomized, placebo- controlled

2019 Effective Health Care Program (AHRQ)

177. Twenty-Five Pearls from 25 years (part 1)

provide harm data including serious adverse events that are not published elsewhere. 13 Donepezil has not been demonstrat- ed to improve outcomes of impor- tance to patients and caregivers (e.g. institutionalization or disability) Drugs for Alzheimer’s Disease [Apr-Aug 2005, issue 56]. Similarly, rivastigmine, galantamine and memantine have not been studied in terms of these important outcomes. It also concludes that acetylcholinesterase inhibitors cause gastrointestinal, muscular and other adverse

2019 Therapeutics Letter

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>